WO1999008666A3 - Pharmaceutical composition comprising an azateroid - Google Patents

Pharmaceutical composition comprising an azateroid Download PDF

Info

Publication number
WO1999008666A3
WO1999008666A3 PCT/EP1998/005194 EP9805194W WO9908666A3 WO 1999008666 A3 WO1999008666 A3 WO 1999008666A3 EP 9805194 W EP9805194 W EP 9805194W WO 9908666 A3 WO9908666 A3 WO 9908666A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
pharmaceutical composition
discloses
azateroid
another aspect
Prior art date
Application number
PCT/EP1998/005194
Other languages
French (fr)
Other versions
WO1999008666A2 (en
Inventor
Alan Frank Parr
Original Assignee
Glaxo Group Ltd
Alan Frank Parr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Alan Frank Parr filed Critical Glaxo Group Ltd
Priority to AU93430/98A priority Critical patent/AU9343098A/en
Priority to CA002295016A priority patent/CA2295016A1/en
Priority to KR19997012116A priority patent/KR20010014080A/en
Priority to JP51280899A priority patent/JP2002511101A/en
Priority to BR9810458-6A priority patent/BR9810458A/en
Priority to EP98946351A priority patent/EP1007010A2/en
Publication of WO1999008666A2 publication Critical patent/WO1999008666A2/en
Publication of WO1999008666A3 publication Critical patent/WO1999008666A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention discloses a novel solution comprising a therapeutically effective amount of a pharmaceutically active aza steroid, and a fatty acid ester of glycerol or propylene glycol. In another aspect, the present invention discloses a pharmaceutical composition comprising the solution of the invention. In another aspect, the present invention discloses a gelatin capsule filled with the composition of the present invention.
PCT/EP1998/005194 1997-08-19 1998-08-17 Pharmaceutical composition comprising an azateroid WO1999008666A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU93430/98A AU9343098A (en) 1997-08-19 1998-08-17 Pharmaceutical composition
CA002295016A CA2295016A1 (en) 1997-08-19 1998-08-17 Pharmaceutical composition
KR19997012116A KR20010014080A (en) 1997-08-19 1998-08-17 Pharmaceutical composition
JP51280899A JP2002511101A (en) 1997-08-19 1998-08-17 Pharmaceutical composition
BR9810458-6A BR9810458A (en) 1997-08-19 1998-08-17 Solution, pharmaceutical composition, and liquid charged gelatin capsule
EP98946351A EP1007010A2 (en) 1997-08-19 1998-08-17 Pharmaceutical composition comprising an azasteroid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9717428.8 1997-08-19
GBGB9717428.8A GB9717428D0 (en) 1997-08-19 1997-08-19 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
WO1999008666A2 WO1999008666A2 (en) 1999-02-25
WO1999008666A3 true WO1999008666A3 (en) 1999-04-15

Family

ID=10817619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/005194 WO1999008666A2 (en) 1997-08-19 1998-08-17 Pharmaceutical composition comprising an azateroid

Country Status (15)

Country Link
EP (1) EP1007010A2 (en)
JP (1) JP2002511101A (en)
KR (1) KR20010014080A (en)
CN (1) CN1263461A (en)
AR (1) AR016629A1 (en)
AU (1) AU9343098A (en)
BR (1) BR9810458A (en)
CA (1) CA2295016A1 (en)
CO (1) CO4960657A1 (en)
GB (1) GB9717428D0 (en)
MA (1) MA26531A1 (en)
PE (1) PE105699A1 (en)
TR (1) TR199903209T2 (en)
WO (1) WO1999008666A2 (en)
ZA (1) ZA987392B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS6633A (en) * 2002-11-22 2004-05-23 Omega Farma Ehf. Compositions of finasteride tablets
KR101152470B1 (en) 2003-08-13 2012-06-01 바이오콘 리미티드 - micro-particle fatty acid salt solid dosage formulations for therapeutic agents
WO2005066195A1 (en) * 2004-01-02 2005-07-21 Pharmacon Forschung Und Beratung Gmbh Method for producing 1,2-unsaturated azasteroids
WO2006055659A2 (en) * 2004-11-15 2006-05-26 Smithkline Beecham Corporation Fixed dose combination op dutasteride and tamsulosin
WO2010117873A2 (en) 2009-04-06 2010-10-14 Banner Pharmacaps, Inc. Progesterone solutions for increased bioavailability
ES2385240B1 (en) 2010-07-26 2013-09-23 Gp-Pharm, S.A. CAPSULES OF ACTIVE PHARMACEUTICAL PRINCIPLES AND POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF PROSTATE DISEASES.
US8900631B2 (en) 2011-04-28 2014-12-02 Health Science Funding, LLC Dosage form to increase prasterone bioavailability
CN103169712B (en) * 2011-12-20 2017-10-27 重庆华邦制药有限公司 Improve dutasteride's preparation of bioavilability and preparation method thereof
WO2014002015A1 (en) 2012-06-25 2014-01-03 Ranbaxy Laboratories Limited Pharmaceutical composition comprising dutasteride
EP2949319A1 (en) 2014-05-26 2015-12-02 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
KR101679992B1 (en) 2015-12-31 2016-11-28 주식회사 유유제약 Pharmaceutical composition comprising dutasteride and propylene glycol monolaurate and preparation method of the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3607651A1 (en) * 1986-03-06 1987-09-10 Schering Ag COMBINATION OF AROMATASE INHIBITORS AND TESTOSTERONE-5 (ALPHA) REDUCTASE INHIBITORS
WO1995007926A1 (en) * 1993-09-17 1995-03-23 Glaxo Wellcome Inc. Androstenones
US5565467A (en) * 1993-09-17 1996-10-15 Glaxo Wellcome Inc. Androstenone derivative
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
EP0742010A2 (en) * 1995-05-10 1996-11-13 Eli Lilly And Company Benzoquinolin-3-ones to inhibit bone loss

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
DE3607651A1 (en) * 1986-03-06 1987-09-10 Schering Ag COMBINATION OF AROMATASE INHIBITORS AND TESTOSTERONE-5 (ALPHA) REDUCTASE INHIBITORS
WO1995007926A1 (en) * 1993-09-17 1995-03-23 Glaxo Wellcome Inc. Androstenones
US5565467A (en) * 1993-09-17 1996-10-15 Glaxo Wellcome Inc. Androstenone derivative
EP0742010A2 (en) * 1995-05-10 1996-11-13 Eli Lilly And Company Benzoquinolin-3-ones to inhibit bone loss

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MATUSZEWSKA B. ET AL: "Comparative bioavailability of L-683453, a 5.alpha. reductase inhibitor from a self emulsifying drug delivery system in beagle dogs", INT. J. OF PHARM., vol. 136, no. 1,2, 1996, pages 147 - 154, XP002092826 *

Also Published As

Publication number Publication date
CO4960657A1 (en) 2000-09-25
PE105699A1 (en) 1999-11-25
MA26531A1 (en) 2004-12-20
CA2295016A1 (en) 1999-02-25
WO1999008666A2 (en) 1999-02-25
GB9717428D0 (en) 1997-10-22
JP2002511101A (en) 2002-04-09
TR199903209T2 (en) 2000-05-22
BR9810458A (en) 2000-09-05
CN1263461A (en) 2000-08-16
EP1007010A2 (en) 2000-06-14
ZA987392B (en) 2000-02-17
KR20010014080A (en) 2001-02-26
AU9343098A (en) 1999-03-08
AR016629A1 (en) 2001-07-25

Similar Documents

Publication Publication Date Title
WO1995017156A3 (en) Ethanol substitutes
ES2186715T3 (en) USE OF A LIPOFILIC TENSIOACTIVE IN A PHARMACEUTICAL COMPOSITION.
IE790704L (en) Cyclosporin composition
CA2109623A1 (en) Process for solubilizing difficultly soluble pharmaceutical actives
ES8503508A1 (en) Pharmaceutical compositions.
WO2000007979A3 (en) Compounds and compositions for delivering active agents
IE940583L (en) Topical antimicrobial pharmaceutical compositions
CA2156288A1 (en) Glycerol derivative, device and pharmaceutical composition
WO2001032596A8 (en) Phenoxy carboxylic acid compounds and compositions for delivering active agents
AU5241199A (en) Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
JO2300B1 (en) Solid lipid formulations
CA2172616A1 (en) Tropyl 7-azaindol-3-ylcarboxyamides as antitussive agent
WO1999008666A3 (en) Pharmaceutical composition comprising an azateroid
WO1999008684A3 (en) Solutions containing azasteroids
HUP9700005A3 (en) 2-ureido-benzamide derivatives and pharmaceutical compositions containing them as active agent
MY120521A (en) Pharmaceutical microspheres of valproic acid for oral administration.
AU8030894A (en) Pharmaceutical compositions comprising a staurosporine as active ingredient.
AU5647199A (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
ZA9811655B (en) Phenylaminoalkylcarboxylic acid derivatives and pharmaceutical compositions comprising the same
AU2773597A (en) Pharmaceutical compositions for the sustained release of insoluble active principles
CA2097827A1 (en) Enhanced bioavailability pharmaceutical composition containing probucol
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
AU5443499A (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
AU8604598A (en) Pharmaceutical formulation for camptothecin analogues in gelatin capsule
WO1994024983A3 (en) Ocular delivery of nucleic acid

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98806380.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/011970

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2295016

Country of ref document: CA

Ref document number: 2295016

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 93430/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998946351

Country of ref document: EP

Ref document number: 1999/03209

Country of ref document: TR

Ref document number: 1019997012116

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 09485570

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998946351

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019997012116

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998946351

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019997012116

Country of ref document: KR